We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.
We also want to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest ideas and work in our company.
We believe our portfolio best meets the varied and often complex needs of patients and societies. Novartis is positioned to lead in innovation, partner with others and offer solutions to patients across a broad healthcare spectrum. In addition, a diverse portfolio reduces financial risk, bringing greater value to those who invest in our company. Our unique portfolio focuses on science-based healthcare sectors that are growing rapidly, reward innovation, and enhance the lives of patients.
Contact
Address: AXA Tower 26th Floor Kuningan City Jl Prof. Dr. Satrio Kav. 18 Setiabudi – Kuningan Jakarta Selatan 12940 Jakarta, Indonesia
Tel. +62 21-3048 0600
Website: https://www.id.
Milan Paleja, country president and general manager of Novartis Indonesia, discusses his main priorities since assuming his current position and the organization’s business expansion strategy, based on enhancing patient access…
The President Director of Novartis Indonesia talks about the strong competition his company faces from local generics manufacturers, and his perspectives on the other challenges currently facing his company in…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer,…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and…
No longer a fledgling biotech, oncology-focused BeiGene, originally created in China in 2010 with the idea of carrying out world-class research there, has since expanded its global reach and garnered…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics;…
A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
While much of PharmaBoardroom’s recent report on Hong Kong and the Greater Bay Area looks at how Hong Kong is attempting to position itself as a development and financing hub…
Thanks to favourable regulations from the Ministry of Health and Prevention (MoHaP) which include fast-track regulatory pathways, patients in the UAE are gaining access to innovative medicines in similar time…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
Pfizer CEO Albert Bourla is the pharma executive with the biggest impact on social media, according to a new study. While busy industry leaders may not currently place social media…
See our Cookie Privacy Policy Here
